Twice-yearly injectable lenacapavir, an HIV-prevention drug, reduces risk by 96%
Lenacapavir, the twice-yearly injectable HIV-1 capsid inhibitor, demonstrated superiority to the once-daily Truvada in a recent Phase 3 clinical trial, Gilead Sciences, Inc. announced on Thursday. It was one of two Phase 3 trials halted early due to …